Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich's ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.